Diabetes Mellitus, Type 2 Clinical Trials in Indianapolis, Indiana

4 studies are recruiting for diabetes mellitus, type 2 in Indianapolis, Indiana right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

   The study is testing UBT251 in participants with type 2 diabetes. The purpose of this clinical study is to find out if UBT251 is effective and safe for treating participants with type 2 diabetes. Participants will either get UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Which treatme…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Midwest Inst For Clin Res, Indianapolis, Indiana

   Locations

   70 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07668388 on ClinicalTrials.gov

2. A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

   The purpose of this clinical study is to look into how well a study medicine called CagriSema helps children and adolescents living with diabetes lower their blood sugar and body weight. The study has 2 parts: in the first part participant will get either CagriSema or placebo, and in the second par…

   Stage

   Phase 3

   Ages

   10 to 18

   Site

   Riley Hospital For Children, Indianapolis, Indiana

   Locations

   58 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07282613 on ClinicalTrials.gov

3. A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

   TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease …

   Stage

   Not phased

   Ages

   55 and older

   Site

   Indiana Medical Research Institute, Indianapolis, Indiana

   Locations

   125 in total

   Run by

   Cleerly, Inc.

   See if you can join NCT06112418 on ClinicalTrials.gov

4. Drug Interaction Potential of Pro-Inflammatory Conditions

   Pro-inflammatory cytokines, which are elevated in pro-inflammatory disease states (e.g., type II diabetes mellitus [T2DM], irritable bowel diseases [IBD], and end stage renal disease [ESRD]) have been shown to inhibit hepatic drug-metabolizing enzymes, including members of the cytochrome P450 (CYP)…

   Stage

   Not phased

   Ages

   12 to 99

   Site

   Indiana University Hospital, Indianapolis, Indiana

   Run by

   Indiana University

   See if you can join NCT07360938 on ClinicalTrials.gov